Latest

3 stories

Hide weekly roundups

Tuesday, September 8

Pharvaris reports positive Phase 3 CHAPTER-3 results for deucrictibant XR in HAE prophylaxis

The company said the trial met its primary and secondary endpoints, with plans to file for marketing authorization starting in the first half of 2027.

SEC filing

Regulatory decisionPharvaris N.V.

Pharvaris reports positive CHAPTER-3 Phase 3 data for deucrictibant XR in HAE prophylaxis

The trial met its primary endpoint with an 83% reduction in attack rate versus placebo, and all secondary endpoints reached statistical significance.

SEC filing

Wednesday, August 12

Regulatory milestonePharvaris N.V.

Pharvaris reports Q2 2026 results, expects CHAPTER-3 data in third quarter

The company said cash reached €318 million as it awaits pivotal HAE data and an April 2027 FDA decision on deucrictibant IR.

SEC filing